Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -14.69% is 74% above its 5-year average of -57.19%, near the high end of its 5-year range (-404.94%–2.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 230.51% below its 12-month average of -4.44%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -14.69%.
RETURN ON INVESTED CAPITAL (ROIC)
-14.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-4.44%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-15.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-57.19%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-230.51%
CURRENT VS 3Y AVG
+3.34%
CURRENT VS 5Y AVG
+74.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+58.79%
vs the sector median at left
GeneDx Holdings Corp.
Market Cap
$2.14B
Return on Invested Capital (ROIC)
-14.69%
TTM Avg
-4.44%
3Y Avg
-15.20%
5Y Avg
-57.19%
Market Cap
$2.11B
Return on Invested Capital (ROIC)
-25.45%
TTM Avg
-178.48%
3Y Avg
-376.60%
5Y Avg
-259.41%
Market Cap
$2.11B
Return on Invested Capital (ROIC)
8.61%
TTM Avg
7.04%
3Y Avg
7.13%
5Y Avg
6.52%
Market Cap
$2.17B
Return on Invested Capital (ROIC)
16.96%
TTM Avg
-12.78%
3Y Avg
-0.83%
5Y Avg
5.59%
Market Cap
$2.10B
Return on Invested Capital (ROIC)
-85.78%
TTM Avg
-36.41%
3Y Avg
-56.32%
5Y Avg
-60.45%
Market Cap
$2.17B
Return on Invested Capital (ROIC)
-61.74%
TTM Avg
-58.38%
3Y Avg
-49.99%
5Y Avg
-42.69%
Market Cap
$2.08B
Return on Invested Capital (ROIC)
3.61%
TTM Avg
5.05%
3Y Avg
-22.39%
5Y Avg
-28.34%
Market Cap
$2.24B
Return on Invested Capital (ROIC)
-26.95%
TTM Avg
-26.95%
3Y Avg
-26.95%
5Y Avg
-26.95%
Market Cap
$2.07B
Return on Invested Capital (ROIC)
-39.18%
TTM Avg
-43.45%
3Y Avg
-43.80%
5Y Avg
-51.45%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | $2.14B | -14.69% | -4.44% | -15.20% | -57.19% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -25.45% | -178.48% | -376.60% | -259.41% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 8.61% | 7.04% | 7.13% | 6.52% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | 16.96% | -12.78% | -0.83% | 5.59% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.10B | -85.78% | -36.41% | -56.32% | -60.45% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | -61.74% | -58.38% | -49.99% | -42.69% |
| Alvotech (ALVO)vs › | $2.08B | 3.61% | 5.05% | -22.39% | -28.34% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -26.95% | -26.95% | -26.95% | -26.95% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | -39.18% | -43.45% | -43.80% | -51.45% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -45.19% | -39.97% | -37.50% | -32.54% |
ROIC
-14.7%
ROE
-43.5%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -14.69% |
| 2026-03-31 | -8.17% |
| 2025-12-31 | -2.67% |
| 2025-09-30 | 2.04% |
| 2025-06-30 | 1.27% |
| 2025-03-31 | -3.74% |
| 2024-12-31 | -6.37% |
| 2024-09-30 | -17.39% |
| 2024-06-30 | -28.94% |
| 2024-03-31 | -38.40% |
| 2023-12-31 | -50.11% |
| 2023-09-30 | -137.44% |
| 2023-06-30 | -132.79% |
| 2023-03-31 | -148.03% |
| 2022-12-31 | -162.12% |
| 2022-09-30 | -68.82% |
| 2022-06-30 | -62.61% |
| 2022-03-31 | -81.30% |
| 2021-12-31 | -97.84% |
| 2021-09-30 | -85.61% |
| 2021-06-30 | -404.94% |
